BMO Capital lowered the firm's price target on Medpace to $400 from $460 and keeps a Market Perform rating on the shares. The company's results were well ahead of consensus, but another quarter of elevated cancellations combined with weaker gross wins weigh heavily on both the longer-term growth outlook and investor sentiment, the analyst tells investors in a research note.
